Formation Bio outlined its AI‑native, hub‑and‑spoke model for accelerating clinical development, combining an integrated execution engine and $600M+ of capital to speed trials and regulatory filings. The company said it focuses AI leverage on clinical development—trial design, execution, and regulatory work—to improve speed and predictability across in‑licensed assets. Concurrently, Latent Labs (ex‑DeepMind team) is positioning AI to design ready‑to‑develop biologics in a single step, claiming models that accelerate candidate selection for challenging targets. Together the two profiles illustrate divergent AI strategies: platformized clinical execution versus generative biologic design. Both signal a maturation of AI in biotech from discovery proofs toward commercialized development funnels.